How to Safely Discontinue Parenteral Nutrition Therapy

September 11, 2025

Understanding the Importance of Safe PN Cessation

Parenteral Nutrition (PN) is a vital therapy for patients unable to meet their nutritional needs via regular diet. However, long-term reliance on PN can lead to complications, signaling the importance of transitioning patients off PN safely. This article delves into the weaning process, protocols, and considerations for safely discontinuing parenteral nutrition, ensuring minimal risk and optimal health outcomes.

Weaning Off Parenteral Nutrition: Key Guidelines

What are the guidelines for weaning off parenteral nutrition?

Weaning off parenteral nutrition (PN) requires careful planning and thorough assessment of the patient's readiness. Healthcare providers evaluate various factors such as weight, nutritional markers, and gastrointestinal function before starting this transition. The individual’s overall health status, surgical history, and current medications play crucial roles in determining when to initiate weaning.

A structured approach entails setting realistic nutrition and hydration goals. For effective weaning, the estimated caloric and fluid intake needs must be tailored to the patient's specific health requirements. Patients are typically transitioned through enteral nutrition (EN) options, which could involve oral supplements or tube feeding. Monitoring adaptation to these new dietary changes is critical.

Key Aspects of the Weaning Process

  • Assessment of Daily Goals: Before weaning begins, ensure that the patient meets daily oral fluid and caloric intake targets.
  • Regular Monitoring: Frequent follow-ups to assess progress include checking nutritional intake, weight changes, serum electrolytes, and hydration levels.
  • Adaptation Importance: The extent of bowel adaptation significantly influences the success of transitioning off PN.
  • Intervention Measures: Consider the application of recombinant human growth hormone or glutamine to aid in the adaptation process.

These guidelines reinforce that gradual transitioning paired with meticulous monitoring can prevent complications such as dehydration and malnutrition during the weaning process.

Protocol for Discontinuing Total Parenteral Nutrition (TPN)

What is the protocol for discontinuing TPN?

A structured approach is critical for safely discontinuing Total Parenteral Nutrition (TPN). It is generally recommended to taper the TPN infusion rate gradually. A suggested method includes lowering the rate to 75 ml/hr for the first 30 minutes, followed by a further reduction to 50 ml/hr during the final 30 minutes before stopping entirely. This gradual decrease helps mitigate the risks associated with abrupt cessation.

Monitoring during tapering

Regular monitoring throughout the tapering process is essential. Healthcare providers should frequently assess the patient’s nutritional status and overall health, focusing on their tolerance to enteral nutrition. Blood work, including electrolytes and glucose levels, should also be checked to detect any potential complications early. Keeping an eye on these metrics helps to adjust the tapering process as necessary to ensure safety.

Blood sugar management

Attention to blood sugar management during this transition is crucial, especially for patients who were previously hyperglycemic on TPN. Fluctuations in blood glucose levels can occur, so monitoring should be done closely, particularly in the early stages of tapering. Patients on insulin may require adjustments to their regimen to accommodate changes in dietary intake after discontinuing parenteral support.

Avoiding Health Complications During TPN Cessation

How should TPN be stopped to avoid health complications?

To stop TPN and avoid health complications, establishing a comprehensive weaning plan is critical. This plan should outline specific goals tailored to the individual’s health needs and set a realistic timeline for transitioning from parenteral to enteral nutrition.

A gradual discontinuation of TPN is essential. Abruptly stopping TPN can lead to rebound hypoglycemia, characterized by dangerously low blood sugar levels. To mitigate this risk, healthcare providers may taper the TPN infusion, reducing the rate gradually before complete cessation.

Monitoring the patient’s nutrition and hydration is also vital during this transition period. It involves assessing gastrointestinal function and ensuring adequate caloric and fluid intake through enteral feeding or oral supplements. Regular follow-ups are necessary to track the patient’s progress and adjust the nutrition plan as needed.

What health assessments should be conducted?

Healthcare assessments should focus on the patient’s nutritional status and overall health. This includes monitoring for complications, such as dehydration or electrolyte imbalances, that can occur as TPN is withdrawn. Evaluating the patient's response to the new diet can inform whether to continue, modify, or restart parenteral nutrition if enteral nutrition is not tolerated within a few days.

A detailed review of the patient's surgical history and current medications will further guide the weaning process, ensuring a safe and effective transition away from TPN.

Cycling Off TPN: A Practical Approach

How do I cycle off TPN safely?

Cycling off Total Parenteral Nutrition (TPN) requires a systematic and monitored approach to ensure safety and efficacy. The process begins with establishing a cyclic TPN schedule. Start by implementing a 1-hour rest window where the patient is off TPN. This small increment allows time to observe for any adverse reactions.

If this initial step is tolerated successfully for 48 hours, the healthcare team can then advance to a 2-hour rest window off TPN. Continuous monitoring during this phase is vital to assess the patient’s tolerance to the dietary adjustment.

Once the 2-hour window is passed without complications, the next goal is to progress to a 4-hour rest window off TPN. The key here is gradual adjustments and ensuring the patient can handle each increment comfortably. This cautious escalation helps mitigate risks associated with abrupt changes, such as blood sugar fluctuations and refeeding syndrome.

What is the step-by-step process for transitioning off TPN?

The process can be summarized as follows:

Step Duration Action
Initial Window 1 hour Patient off TPN
Monitor for tolerance 48 hours Evaluate patient's adaptation
Next Window 2 hours Patient off TPN
Monitor for tolerance 48 hours Evaluate again
Final Goal 4 hours Patient off TPN

How is patient tolerance assessed during TPN weaning?

Throughout the weaning process, healthcare providers assess the patient's physiological responses, including blood glucose levels and signs of dehydration. Maintaining regular communication and follow-ups helps adjust the feeding plan as necessary based on individual needs and responses. This ongoing evaluation ensures a smooth transition to an enteral or oral nutrition regimen while minimizing potential complications.

The Role of Enteral Nutrition in Transitioning off PN

Introducing enteral nutrition

Transitioning from parenteral nutrition (PN) to enteral nutrition (EN) is a critical process requiring careful planning and execution. When introducing enteral nutrition, practitioners typically begin with small volumes of feeding to assess the patient's tolerance. It is essential to gradually increase these volumes based on the patient's adaptability to avoid gastrointestinal discomfort or distress.

Monitoring adaptation

Ongoing monitoring is vital during this transition phase. Healthcare providers should watch for symptoms indicative of intolerance, including nausea, vomiting, or any signs of distress. Patients should ideally achieve 60%-75% of their caloric and protein needs via EN for a sustained period of 48-72 hours to ensure they can successfully shift off PN. This careful approach helps in identifying potential issues early on and adjusting the dietary plan accordingly.

Risks and thresholds

While transitioning off PN, understanding the risks associated with fluid management and refeeding syndrome is crucial. The thresholds for safe discontinuation of PN are generally established at achieving over 100 ml/kg enteral nutrition per day, with higher volumes suggested for high-risk populations, such as extremely low birth weight infants. Adequate nutritional intake is paramount to prevent complications like malnutrition or metabolic abnormalities as patients adapt to their new feeding regimen.

Focus Area Key Points Action Required
Introducing EN Start small, monitor tolerance Gradual increment based on results
Monitoring adaptation Watch for signs of distress Adjust feeding volumes accordingly
Risks and thresholds Discontinue PN at ≥100 ml/kg EN/day for safety Regular assessment of nutritional status

Assessing Gastrointestinal Function and Adaptation

Why is evaluating gastrointestinal function important before discontinuing PN?

Evaluating gastrointestinal (GI) function is essential before discontinuing parenteral nutrition (PN) because it directly influences a patient's ability to absorb nutrients effectively. A thorough assessment helps identify any anatomical issues, such as lesions or resection sites from previous surgeries, which can hinder absorption capacity.

Several factors are considered during this evaluation:

  • Gastrointestinal Anatomy : Variations in the structure due to surgeries or congenital conditions can impact nutrient absorption.
  • Absorption Capacity : Patients with conditions like short bowel syndrome may require closer monitoring and a more gradual transition off PN.
  • Existing Conditions : Assessing for any gastrointestinal disorders that may disrupt normal function is key.

Medical evaluations often reveal these factors, helping healthcare providers set realistic goals for enteral nutrition (EN) and tailor strategies that align with the patient's health needs. Adjustments to intake volumes may be necessary based on the patient's adaptation to new nutritional methods.

It is crucial to ensure the safe transition from PN to enteral nutrition and mitigate potential complications associated with malnutrition, such as dehydration and electrolyte imbalances. Regular follow-ups help in adjusting nutritional plans as needed.

Fluid Management and Nutrition Goals

How should fluid and nutritional goals be managed during TPN weaning?

Fluid and nutritional goals during the weaning process from Total Parenteral Nutrition (TPN) should be tailored to the individual's specific health conditions and needs. It is essential to maintain hydration while also ensuring that caloric intake meets the patient’s requirements. Goals must be realistic, focusing on both hydration and nutrition to avoid complications during this transition.

Proper fluid management is critical. Fluids should be replaced independently from feeding sessions because osmotic gradients can decrease fluid absorption capabilities. This is particularly important for patients with gastrointestinal challenges who may struggle with absorption.

Monitoring hydration and ensuring nutrient delivery

Continuous monitoring of hydration levels is crucial during the transition from TPN. Healthcare providers need to assess the patient's risk for dehydration actively and adjust fluid intake accordingly. Regular checks for signs of dehydration or other complications, such as low blood sugar, are part of effective management.

Understanding osmotic gradients

The impact of osmotic gradients cannot be ignored. These gradients can hinder fluid absorption, necessitating careful planning of fluid replacement and nutrition delivery strategies. Providers should be vigilant about making adjustments based on the patient's tolerance and the effectiveness of the nutrition plan as they transition away from TPN.

Managing Complications and Risks Associated with PN

What are the risks and complications to monitor for when discontinuing PN?

Discontinuing parenteral nutrition (PN) requires careful oversight due to potential complications that may arise. Among the most critical risks include:

  1. Infection : Central venous catheters (CVC) used for PN can introduce infection. Hence, maintaining proper hygiene and sterile techniques during administration and monitoring for signs of infection is crucial.

  2. Electrolyte Imbalances : Abrupt changes in nutrition can lead to shifts in electrolytes. Regular assessments of blood electrolyte levels are essential to prevent conditions like hypokalemia or hyperkalemia.

  3. Hypoglycemia : After cessation of PN, patients may experience low blood sugar levels, especially if they were previously hyperglycemic while on nutrition therapy. Monitoring blood glucose continuously is critical during the transition.

Monitoring protocols

Monitoring protocols should be detailed and regular. A typical routine includes:

  • Daily checks of blood glucose levels and electrolytes.
  • Assessing hydration status to avoid complications like dehydration.
  • Keeping track of any symptoms related to potential complications, such as dizziness or confusion, which can indicate low blood sugar.

Infection risk

Given the inherent risks associated with CVC management, special attention should be given to:

  • Keeping the catheter site clean and well-dressed.
  • Ensuring that all personnel involved in PN administration follow strict aseptic protocols.
  • Regularly evaluating the need for continued catheter use to minimize infection risk during nutritional transitions.

Ethical Considerations for Stopping Nutrition Support

What ethical considerations arise when discontinuing artificial nutritional support in terminally ill patients?

In the context of terminally ill patients, the decision to discontinue artificial nutritional support raises significant ethical concerns. Evidence indicates that such interventions often do not enhance survival rates or improve comfort. In many cases, they may inadvertently heighten suffering. Therefore, one ethical perspective is the principle of futility; if the treatment does not provide meaningful benefits for the patient, it may be justified to withdraw it.

Comfort Care and Quality of Life

Transitioning to comfort care focuses on alleviating any distress rather than prolonging life at all costs. Studies show that a substantial portion of terminally ill patients report no hunger when artificial feeding is withheld. This suggests that voluntary limitation of food and fluid intake can align with respecting patients' wishes and prioritizing their comfort during their final days.

Futile Treatments

The withdrawal of unrequested nutrition can further adhere to the principle that futile treatments should not be offered, especially when they do not contribute positively to a patient's prognosis or comfort. For healthcare providers and families, it's crucial to navigate these sensitive discussions with empathy, ensuring decisions are made in the best interest of enhancing patient dignity and quality of life.

The Importance of Patient Education in the Transitioning Process

Why is patient education crucial when weaning off parenteral nutrition?

Patient education is essential during the weaning process from parenteral nutrition (PN). It empowers individuals to actively participate in their care and understand their nutritional needs. When a patient is informed about the transition from PN to enteral nutrition (EN), they are better equipped to adhere to dietary protocols.

Moreover, understanding the gradual changes that are necessary during this transition is vital for several reasons:

  • Monitor Health : Education helps patients recognize signs of complications, such as dehydration or low blood sugar, which can arise during the weaning phase.
  • Nutritional Understanding : Patients learn the importance of caloric intake and hydration tailored to their specific health needs.
  • Engaged Participation : When patients are educated, they become partners in their care, fostering a sense of responsibility and compliance with their health plans.

Overall, informed patients are likely to follow prescribed protocols more closely, reducing risks associated with the transition process and improving outcomes. Regular follow-up is also crucial, allowing healthcare providers to assess the patient's progress and ensure they are successfully adapting to dietary changes.

Research Insights on PN Discontinuation

What have studies found about the discontinuation of PN in various patients?

Research shows varying thresholds for safely discontinuing parenteral nutrition (PN) based on patient needs, age, and overall health conditions. For example, in infants, PN may be safely stopped when enteral nutrition (EN) reaches more than 100 ml/kg/day. In some instances, especially for extremely low birth weight babies, it is advised to discontinue PN only after EN levels reach between 140-150 ml/kg/day. This balance is crucial to mitigate risks associated with prolonged PN use, such as infections and liver disease.

Meanwhile, clinical studies involving adult patients indicate that managing the transition to enteral feeding requires diligent assessment of gastrointestinal function and nutritional markers. Research emphasizes that stopping PN should not be abrupt but gradual, especially in patients who were previously hyperglycemic while on PN therapy. This careful adjustment can help avoid complications such as hypoglycemia and ensure that the patient's dietary needs are met adequately.

Evidence-based practices regarding PN discontinuation

Evidence-based guidelines suggest initiating enteral nutrition gradually, beginning with small volumes and progressively increasing to assess tolerance. It is pivotal to monitor patients closely during this transition phase for any signs of dehydration or abnormal blood sugar levels. The need for continuous glucose monitoring for those on insulin therapy cannot be understated, as fluctuations can compromise the transition process.

Clinical implications of careful PN management

The approach to safely discontinue PN not only involves individualized assessment but also a commitment to continuous follow-up and adaptation of nutritional strategies. This is vital to preventing complications associated with abrupt cessation. As patients move towards a more independent nutritional regimen, healthcare providers must remain vigilant to promote patient safety and improve overall health outcomes.

Conclusion: Ensuring a Safe Transition from PN

Successfully discontinuing parenteral nutrition involves a comprehensive approach that prioritizes patient safety, adherence to clinical guidelines, and thorough monitoring of both health and nutritional intake. Through careful planning, patient education, and adherence to evidence-based protocols, healthcare providers can support patients in effectively transitioning from parenteral to enteral or oral nutrition, minimizing risks and promoting better health outcomes.

References

Dialysis center staff coordinating phosphate binder supply with a pharmacy partner
August 11, 2026
What dialysis centers should look for in a phosphate binder supply partner: reliable delivery, formulary breadth, insurance support, and coordination.
Renal dietitian reviewing phosphate levels with a dialysis patient
August 11, 2026
How hyperphosphatemia is managed in ESRD dialysis patients, diet, dialysis, and phosphate binders, and why reliable binder supply keeps therapy on track.
July 29, 2026
Compounded medications are a routine part of modern care, but unlike mass-manufactured drugs, each one is prepared individually, which means the standards behind its preparation carry real weight. For providers who order or refer for compounded therapies, a working understanding of those standards is the clearest way to judge whether a pharmacy is safe to trust. This overview covers the standards that govern sterile compounding and what they mean for the medications your patients receive. Why Standards Matter More in Compounding A commercially manufactured drug is produced under FDA oversight in large, validated batches. A compounded medication is prepared for an individual patient, often in small quantities, sometimes because no commercial equivalent exists. That flexibility is exactly why it's clinically valuable — and why the standards around preparation exist. Without rigorous controls, the same customization that helps patients could introduce contamination or error. Our guide to our sterile compounding pharmacy describes how those controls come together in practice. The Regulatory Landscape Sterile compounding sits within a layered framework: The United States Pharmacopeia (USP) publishes the general chapters, most importantly <797> and <800>, that define how compounded preparations should be made and handled. State boards of pharmacy license and inspect pharmacies, including where they're permitted to ship. Multi-state operations must maintain licensure in each state they serve. Accreditation bodies (ACHC, NABP, PCAB) provide independent verification that a pharmacy meets recognized standards. Together, these create the accountability structure behind every compounded dose. USP <797>: Sterile Preparations USP <797> is the cornerstone standard for compounded sterile preparations. It governs the conditions and practices required to keep a preparation free of contamination, including personnel training and garbing, ISO-classified air quality and engineering controls, environmental monitoring, and beyond-use dating. For any medication infused directly into the body, <797> compliance is the baseline expectation, not a premium feature. USP <800>: Hazardous Drugs USP <800> adds a containment layer for hazardous drugs, protecting personnel, patients, and the environment from unintended exposure. It specifies containment engineering controls, PPE, and validated handling procedures for drugs identified as hazardous. When a preparation is both sterile and hazardous, it must satisfy <797> and <800> together. For the details, see our breakdown of USP <800> requirements . Accreditation: Independent Verification Standards are only meaningful if someone checks that they're being met. Accreditation from ACHC, NABP, and PCAB means a pharmacy has been inspected against national benchmarks by an outside authority. For a provider, accreditation is a shortcut to confidence: it signals that the pharmacy's claims about its processes have been independently validated. The Quality-Control Process Behind the standards is a repeatable process that governs each preparation: Pharmacist review of the prescription for appropriateness, compatibility, and dosing Preparation by trained technicians under aseptic conditions In-process and final verification by a licensed pharmacist Sterility testing or filtration validation where required This chain is what turns a standard on paper into a safe medication in a patient's hands. What This Means When You Order When you refer a patient for a compounded therapy, you're effectively extending your own standard of care into another facility. Knowing that a pharmacy is USP-compliant, accredited, and pharmacist-led lets you refer with confidence that the medication will meet the same expectations you'd hold for anything you administer yourself. If you're weighing options, our guide on how to choose a compounding partner walks through the criteria. The Pharmko Standard Pharmko compounds every TPN, IDPN, and IPN preparation in a USP <797>-compliant, ISO Class 5 cleanroom, under ACHC, NABP, and PCAB accreditation, with a licensed pharmacist reviewing and releasing each formula. For the patients who receive our preparations, many of them managing End Stage Renal Disease (ESRD), that standard is the point. Refer a Patient → · [1 (877) 540-2003]
Physician evaluating a sterile compounding pharmacy partner
July 29, 2026
How to evaluate a sterile compounding pharmacy: accreditation, USP compliance, clinical support, turnaround, and the questions every practice should ask.
Sterile compounding pharmacy technician in PPE under a containment hood
July 29, 2026
A clear guide to USP 800 requirements: hazardous drug handling, containment, PPE, and the facility standards every sterile compounding pharmacy must meet.
Myasthenia Gravis and IVIG: What Patients Need to Know About IV Therapy
July 20, 2026
Learn how IVIG therapy works for myasthenia gravis, when it's used, what to expect during infusions, how home IVIG is coordinated, and how Pharmko supports MG patients and their neurologists.
Dobutamine and Inotrope Therapy at Home
July 17, 2026
Learn how home dobutamine infusion works for advanced heart failure, who qualifies, how continuous inotrope therapy is managed at home, and how Pharmko supports cardiac patients and heart failure teams.
CIDP and Home Infusion: IVIG Treatment, Dosing Schedule, and Long-Term Management
July 16, 2026
Learn how IVIG therapy works for CIDP, what the dosing schedule looks like, how to transition to home infusion, and how Pharmko supports long-term CIDP management across 22+ states.
Compounded IV Medications
July 15, 2026
Most medications that patients receive at a hospital or pharmacy come in standardized, commercially manufactured forms, a 500mg antibiotic vial, a pre-filled syringe, a fixed-concentration IV bag. These products work well for many patients. But a significant portion of patients receiving IV therapy have clinical needs that commercial products cannot meet: a dose the manufacturer doesn't make, a formulation incompatible with the patient's allergy profile, or a combination of nutrients that must be tailored to individual lab values. For these patients, compounded IV medications are not optional, they are clinically necessary. Pharmko's sterile compounding services prepare customized IV medications for patients across 22+ states, with every formulation reviewed by a licensed pharmacist and prepared in a USP <797> compliant cleanroom. What Makes an IV Medication 'Compounded'? A compounded medication is one that is prepared specifically for an individual patient by a licensed pharmacist, rather than manufactured in bulk by a pharmaceutical company. Compounding involves combining, mixing, or altering ingredients, active pharmaceutical ingredients, diluents, preservatives, to create a final preparation that meets the patient's unique prescription requirements. For IV therapy specifically, compounding means preparing a sterile preparation, one that is completely free of viable microorganisms and safe to inject or infuse directly into the bloodstream. This requires specialized facilities, equipment, training, and quality systems that go far beyond what a standard retail pharmacy can provide. Pharmko is exclusively a sterile compounding pharmacy. We do not compound oral medications, topical creams, or non-sterile preparations. Every product we make is intended for intravenous, intraperitoneal, or subcutaneous administration. When Are Compounded IV Medications Necessary? The required dose doesn't exist commercially Pharmaceutical manufacturers produce medications in standardized strengths and volumes based on average patient needs. Pediatric patients, patients with renal or hepatic impairment requiring dose adjustments, or patients whose weight or clinical status falls outside standard ranges may need concentrations or volumes that no commercial product provides. Compounding fills this gap precisely. The patient has an allergy to a commercial formulation's inactive ingredients Commercial IV products often contain preservatives, stabilizers, or diluents, sulfites, benzyl alcohol, certain dyes, that some patients cannot tolerate. A compounding pharmacy can prepare an equivalent formulation without the offending ingredient, allowing the patient to receive the therapy safely. The medication requires individualized nutrient formulation Total parenteral nutrition (TPN) is the clearest example: every TPN formula must be individually compounded because no commercial product can provide the precise combination of amino acids, dextrose, lipids, electrolytes, vitamins, and trace minerals a specific patient needs. The formula changes as the patient's labs, weight, and clinical status change, making standardization impossible. The commercial product is unavailable or in shortage Drug shortages are a persistent reality in the US pharmaceutical supply chain. When a commercially manufactured IV medication becomes unavailable, compounding pharmacies can often prepare an equivalent formulation from available active pharmaceutical ingredients, bridging the gap and maintaining continuity of therapy for patients who cannot wait. The therapy requires a custom delivery format Some IV medications require specific pH, osmolarity, or concentration adjustments for compatibility with a patient's IV access device or concurrent medications. A compounding pharmacist reviews compatibility and prepares formulations that are safe and stable for the specific administration route and equipment the patient is using. How Compounded IV Medications Are Made Step 1: Prescription review Every compounded IV medication begins with a valid prescription from a licensed prescriber. Pharmko's pharmacists review the prescription for clinical appropriateness, dosing accuracy, ingredient compatibility, and stability before compounding begins. Step 2: Ingredient sourcing and verification Active pharmaceutical ingredients for compounding must come from FDA-registered suppliers and meet USP monograph specifications. Each lot is verified for identity, potency, and purity before use. Step 3: Sterile preparation in a controlled environment Preparation occurs in an ISO Class 5 laminar airflow workbench or biological safety cabinet, located within a buffer room that meets ISO Class 7 air quality standards. Pharmacy technicians follow validated, written procedures for each preparation type, using aseptic technique to prevent contamination at every step. Step 4: Pharmacist verification and release A licensed pharmacist performs a final check of every preparation, verifying appearance, volume, labeling, and documentation, before the product is released. High-risk or complex preparations may undergo sterility testing with defined beyond-use dates based on test results. Step 5: Cold-chain delivery Most compounded IV medications require refrigeration. Pharmko uses validated cold-chain packaging and delivery logistics to ensure products arrive within their stability windows and remain temperature-controlled until the patient uses them. Quality Standards That Matter Not all compounding pharmacies operate at the same standard. The relevant quality benchmarks for sterile compounding are: USP <797> compliance, the national standard for sterile compounding environments, personnel, and processes. Our guide on USP <797> and USP <800> explains what compliance means in practice ACHC accreditation, independent third-party verification that Pharmko meets clinical quality standards for home infusion and sterile compounding State pharmacy board licensure, Pharmko is licensed in every state where we serve patients Environmental and personnel monitoring, documented air and surface sampling, personnel gowning competency assessments, and media fill testing at defined intervals For a foundational overview of what sterile compounding is and how it differs from retail pharmacy, see our guide on what is sterile compounding for IV therapy . → Contact Pharmko about compounded IV medications: 1-877-540-2003
home infusion therapy Pennsylvania
July 14, 2026
Pharmko provides home infusion therapy across Pennsylvania, IV antibiotics, IVIG, TPN, biologics, and specialty medications. Licensed, ACHC accredited, and available 24/7 statewide.
Show More